ALFACELL CORP
8-K, 1996-07-16
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: SCOUT STOCK FUND INC, N-30B-2, 1996-07-16
Next: MAXTOR CORP, S-8, 1996-07-16



<PAGE>
                  SECURITIES AND EXCHANGE COMMISSION

                        WASHINGTON, D.C.  20549

                               FORM 8-K

                            CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of

Report (Date of earliest event reported)  JUNE 11, 1996

                         ALFACELL CORPORATION

         (Exact  name  of  registrant  as  specified in its charter)




       DELAWARE                    0-11088              22-2369085
   (State or other jurisdiction   (Commission          (IRS Employer
       of incorporation)         File Number)          Identification)



        225 BELLEVILLE AVENUE  BLOOMFIELD,  NEW JERSEY  07003
          (Address of principal executive offices)       (Zip Code)



Registrant's telephone number, including area code    (201) 748-8082




     (Former name or former address, if changed since last report)
<PAGE>


ITEM 5.  OTHER EVENTS.

     In June 1996 Alfacell Corporation (the "Company")  completed a private
placement (the "June 1996 Private Placement") resulting in  the issuance of
1,722,646 shares of common stock, $.001 par value (the "Common  Stock") and
313,800 three year warrants (the "Warrants") each to purchase one  share of
Common  Stock  at  an  exercise  price  of  $7.50  per share to private and
institutional investors.  The Common Stock was sold  alone  for  $3.70  per
share and in units, each consisting of three shares of Common Stock and one
Warrant,  at  a  per  unit price of $12.52. The June 1996 Private Placement
resulted in net proceeds  to the Company of approximately $5,700,000, after
the payment of certain expenses  in  connection  with the offering.  During
May and June 1996 stock options held by certain members  of  management and
others were exercised resulting in the issuance of an aggregate  of 241,600
shares  of  Common  Stock  and  approximately  $794,000  in proceeds to the
Company.

     The  following  table sets forth the balance sheet of the  Company  at
April 30, 1996 and as  adjusted  on  an unaudited pro forma basis solely to
reflect the net proceeds received subsequent  to  April  30,  1996 from the
issuance and sale of shares of Common Stock and Warrants in the  June  1996
Private  Placement  and  proceeds from the exercise of stock options in May
and June 1996.  Information  as  of  April  30,  1996  was derived from the
Company's quarterly report on Form 10-QSB for the quarter  ended  April 30,
1996  and  the  following  table  should  be  read in conjunction with such
quarterly report.
<PAGE>

                                 April 30, 1996

<TABLE>
<CAPTION>
                              ASSETS                                                           Unaudited
                                                                     Actual                     Proforma
                                                                (UNAUDITED)                  AS ADJUSTED
<S>                                                <C>       <C>            <C>          <C>
Current assets:
     Cash                                          $               657,043            $       7,146,748
     Marketable securities (at cost which                                 
         approximates fair value)                                1,700,000                    1,700,000
     Prepaid expenses                                               90,746                       90,746
          Total current assets                                   2,447,789                    8,937,494
Property and equipment, net of accumulated        
  depreciation and amortization of $682,190 at April
  30, 1996                                                         114,602                      114,602  

Other assets:
     Deferred debt costs, net                                       25,062                       25,062
     Other                                                          28,454                       28,454
                                                                    53,516                       53,516
          Total assets                             $             2,615,907            $       9,105,612


                                  LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
     Current portion of long-term debt             $                93,280            $          93,280
     Loans and interest payable, related party                       1,250                        1,250
     Accounts payable                                              351,764                      351,764
     Accrued payroll and expenses, related parties                 209,046                      209,046
     Accrued expenses                                              139,289                      139,289
          Total current liabilities                                794,629                      794,629

Long-term debt, less current portion                             1,418,448                    1,418,448
          Total liabilities                                      2,213,077                    2,213,077

Commitments and contingencies

Stockholders' equity:
     Preferred stock, $.001 par value                                           
          Authorized and unissued, 1,000,000
          shares at April 30, 1996                                     --                            --    
     Common stock $.001 par value                                   
          Authorized 25,000,000 shares at April
          30, 1996;
          Issued and outstanding 11,900,679 shares
          at April 30, 1996 and 13,657,609 shares at April
          30, 1996 as adjusted                                      11,901                       13,657 
     Capital in excess of par value                             39,996,257                   46,484,205

     Deficit accumulated during development stage              (39,605,327)                 (39,605,327)
          Total stockholders' equity                               402,830                    6,892,535
          Total liabilities and stockholders' equity        $    2,615,907                 $  9,105,612
          
</TABLE>
<PAGE>


                            SIGNATURES


          Pursuant to the requirements of the Securities  Exchange  Act  of

1934, the Registrant has duly caused this report to be signed on its behalf

by the undersigned hereunto duly authorized.




Dated:  July 16, 1996




                                        ALFACELL CORPORATION
                                        (Registrant)

                                   By:  /s/ GAIL E. FRASER
                                        GAIL E. FRASER
                                        Vice President, Finance
                                        and Chief Financial Officer





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission